Amgen Criticizes Roche’s Anemia Study

Law360, New York (July 21, 2006, 12:00 AM EDT) -- Amgen Inc., the largest biotechnology company in the world, reiterated Thursday that it will continue legal action against Roche Holding AG for alleged infringement of the patents to a pair of blockbuster anemia drugs.

The announcement came a few days after Roche, a Swiss drug maker, released a study showing that its drug Mircera could be taken less frequently and still be just as effective as two Amgen drugs, Epogen and Aranesp.

According to Roche, dialysis patients could take Mircera once a month and control their...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.